Reviva Pharmaceuticals Holdings, Inc. (RVPH): Price and Financial Metrics
RVPH Price/Volume Stats
| Current price | $4.33 | 52-week high | $9.25 |
| Prev. close | $4.18 | 52-week low | $3.50 |
| Day low | $4.07 | Volume | 219,800 |
| Day high | $4.34 | Avg. volume | 374,904 |
| 50-day MA | $4.18 | Dividend yield | N/A |
| 200-day MA | $5.05 | Market Cap | 120.89M |
RVPH Stock Price Chart Interactive Chart >
Reviva Pharmaceuticals Holdings, Inc. (RVPH) Company Bio
Reviva Pharmaceuticals Holdings, Inc. operates as a clinical development pharmaceutical company. The Company focuses on developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva Pharmaceuticals Holdings serves customers worldwide.
Latest RVPH News From Around the Web
Below are the latest news stories about REVIVA PHARMACEUTICALS HOLDINGS INC that investors may wish to consider to help them evaluate RVPH as an investment opportunity.
Karuna downgraded, Arm target raised: Wall Street's top analyst callsKaruna downgraded, Arm target raised: Wall Street's top analyst calls |
Life Science Investor Forum: Presentations Now Available for Online ViewingCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Investor Forum sponsored by Zacks Small-Cap Research. held December 14th are now available for online viewing. REGISTER NOW AT: https://bit.ly/41oBqxg The company presentations will be available 24/7 for 90 days. Investors, adv |
Life Science Investor Forum Agenda Announced for December 14th, 2023NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held December 14th. This event is sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3tcvQkSIt is recommended that investors pre-register and run the online system check to expedite participat |
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor ForumCUPERTINO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will participate live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferen |
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceCUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, and Narayan Prabhu, CFO of Reviva, will participate in The Benchmark Company’s Discovery One-on-One In |
RVPH Price Returns
| 1-mo | 0.81% |
| 3-mo | -24.70% |
| 6-mo | 4.84% |
| 1-year | 1.17% |
| 3-year | -53.44% |
| 5-year | N/A |
| YTD | -15.92% |
| 2023 | 21.18% |
| 2022 | 47.06% |
| 2021 | -66.95% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...